Clinical Trial Update: Adaptive Therapy for Post-Second-Line Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adaptive therapy for post-second-line HER2-negative metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Sun Yat-sen University | Conditions: HER2-negative Metastatic Breast Cancer | Phase 2 | Status: COMPLETED